What is the recommended approach to managing hyperglycemia-induced seizures in adults?

Management of Hyperglycemia-Induced Seizures

The primary treatment for hyperglycemia-induced seizures is aggressive correction of hyperglycemia with insulin and hydration, NOT antiseizure medications, which are often ineffective and may even worsen seizures in this specific metabolic context 1, 2.

Key Clinical Recognition Features

Hyperglycemia-related seizures present with a distinctive pattern that should trigger immediate suspicion:

• Focal motor seizures are the predominant type (49.4% of cases), particularly involving the face and upper extremities 1
• Visual seizures are common (23.2%), manifesting as hallucinations or visual disturbances, typically arising from occipital cortex involvement 1, 3
• Seizure clustering occurs in 63% of initial presentations, significantly higher than non-hyperglycemic seizures 4
• Reflex seizures occur in 10.5% of cases 1
• Approximately 40% of patients have newly diagnosed diabetes at presentation 1

The typical patient is an adult (mean age 61 years) presenting with new-onset focal seizures, often without prior diabetes history 1.

Diagnostic Thresholds and Imaging

Mean glycemia at presentation is approximately 530 mg/dL with osmolarity around 310 mmol/mol 1. However, the absolute glucose level does not predict seizure occurrence—patients with and without seizures can have similar glucose levels 5.

Brain MRI shows characteristic findings in 48.7% of cases 1:

• Focal T2 subcortical hypodensity
• Overlying cortical T2 hyperintensity
• DWI restriction
• These changes typically involve motor or posterior cortices 1, 6

Treatment Algorithm

Primary Treatment: Metabolic Correction

1. Immediate insulin therapy with aggressive hydration is the definitive treatment 2, 6
2. Target rapid normalization of blood glucose and osmolarity
3. Monitor for seizure resolution as glucose normalizes

Role of Antiseizure Medications

Antiseizure medications (ASMs) should generally be avoided or used minimally because:

• They achieve seizure control in only 18.3% of cases when administered 1
• They may paradoxically worsen hyperglycemia-related seizures 1, 2
• Seizures typically resolve with metabolic correction alone 3, 2

However, ASMs may be considered in select cases:

• When seizures persist despite adequate glycemic control 6
• In epilepsia partialis continua-like states 7
• When seizures are severe and life-threatening during the correction phase

If ASMs are used, the evidence from status epilepticus guidelines suggests levetiracetam, fosphenytoin, or valproate have similar efficacy 8, though this is extrapolated from general seizure management rather than hyperglycemia-specific data.

Critical Prognostic Factors

HbA1c levels predict seizure severity and recurrence 4:

• HbA1c >9% is associated with significantly higher risk of seizure recurrence (44.8% vs 8.3%)
• HbA1c >9% increases seizure clustering risk (79.3% vs 25%)
• Patients with seizure recurrence had mean HbA1c of 11.8% vs 8.6% in those without recurrence

Higher osmolarity levels correlate with:

• Newly diagnosed diabetes (p=0.002)
• Additional neurological symptoms beyond seizures (p<0.001) 1

Common Pitfalls to Avoid

1. Do not reflexively administer ASMs as you would for typical seizures—this delays definitive treatment and is often ineffective
2. Do not dismiss focal seizures in diabetic patients as simple hypoglycemia—hyperglycemia causes focal seizures while hypoglycemia typically causes generalized seizures
3. Do not assume normal glucose excludes the diagnosis—investigate recent glucose trends and HbA1c
4. Do not overlook visual symptoms—these may represent occipital seizures rather than diabetic retinopathy
5. Do not continue ASMs long-term—once glucose is controlled, seizures typically resolve and ASMs can be discontinued 3

Long-term Management

After acute resolution, aggressive long-term glycemic control is essential to prevent seizure recurrence 4. Patients with poor glycemic control (HbA1c >9%) have dramatically higher recurrence rates. The goal should be HbA1c <9%, ideally <7%, to minimize neurological complications 9, 4.

Vision loss can be irreversible if treatment is delayed, making early recognition and aggressive glucose correction critical 7.